| Vancomycin group | Gentamicin group | oATB group | P |
---|---|---|---|---|
N (%) | 7 (15) | 20 (43) | 19 (41) | Â |
Age (years) | 65 (47–76) | 59 (47–72) | 65 (63–68) | 0.785 |
Male n (%) | 4 (57) | 13 (65) | 13 (68) | 0.866 |
BMI (kg/m2) | 26.2 (23.3–27.8) | 28.4 (24.0–32.5) | 26.3 (24.7–30.9) | 0.620 |
SOFA score (%) | 10 (7–14) + 1 QuickSOFA | 8 (5–12) | 7 (3–10) | 0.406 |
AKI stage at baseline/end of study, all n (%) | ||||
 1 | 1 (14) / 1 (14) | 5 (25) / 3 (15) | 4 (21) / 3 (16) | 0.836/0.995 |
 2 | N | 5 (25) / 1 (20) | 6 (32) / 0 | 0.243/0.515 |
 3 | 2 (29) / 2 (29) | 2 (10) /5 (5) | 6 (32) / 9 (47) | 0.236/0.318 |
No AKI | 4 (57) / 4 (57) | 8 (40) / 11 (55) | 3 (15) / 7 (37) | 0.088/0.455 |
RRT initiation, n (%) | 2 (2) | 5 (25) | 7 (37) | 0.719 |
Use of vasopressors, n (%) | 6 (86) | 15 (75) | 11 (58) | 0.307 |
Type of vasopressor, n (%) | ||||
 Norepinephrine | 6 (100) | 14 (93) | 8 (73) | 0.172 |
 Dobutamine | N | N | 1 (9) | 0.484 |
 Dopamine | N | N | 1 (9) | 0.484 |
 Norepinephrine + Dobutamine | N | 1 (7) | 1 (9) | 0.416 |
Dose of vasopressors (μg/kg/min) | ||||
 Norepinephrine | 0.18 (0.14–0.23) | 0.21 (0.17–0.29) | 0.32 (0.22–0.45) | 0.104 |
 Dobutamine | N | N | 1.79 (1.19–2.38) | 0.333 |
 Dopamine | N | N | 24.41 (19.41–29.41) | 0.333 |
 Norepinephrine / Dobutamine | N / N | 0.14 (0.001–0.28) / 1.04 (0.69–1.39) | 0.24 (0.002–0.48) / 11.63 (0.16–23.10) | 0.467/0.600 |
Duration of vasopressors therapy (days) | 10 (6–12) | 6 (2–9) | 6 (3–13) | 0.256 |
ICU hospitalized patients, n (%) | 6 (86) | 18 (90) | 15 (79) | 0.629 |
ICU length of stay (days) | 18 (11–38) | 13 (9–23) | 12 (10–22) | 0.585 |
Intermediate care hospitalized patients, n (%) | 1 (14) | 2 (10) | 4 (21) | 0.629 |
Intermediate care length of stay (days) | 12 | 9 (8–10) | 16 (10–24) | 0.438 |
Total length of hospitalization (days) | 31 (12–52) | 25 (15–35) | 17 (12–24) | 0.162 |
Diagnoses, all n (%) | Â | Â | Â | Â |
Urogenital infection | 2 (29) | 4 (20) | 5 (26) | 0.856 |
Pneumonia | Â | Â | Â | Â |
 - Nosocomial | 1 (14) | 2 (10) | 2 (11) | 0.950 |
 - Community acquired | N | N | 2 (11) | 0.226 |
Sepsis in severe trauma | 1 (14) | 4 (20) | N | 0.127 |
Peritonitis | 1 (14) | 6 (30) | 1 (5) | 0.122 |
Mediastinitis | 1 (14) | 1 (5) | N | 0.280 |
Liver abscess | 1 (14) | N | N | 0.058 |
Acute cholecystitis | N | N | 1 (5) | 0.484 |
Acute pancreatitis | N | N | 1 (5) | 0.484 |
Infectious gastroenteritis | N | N | 1 (5) | 0.484 |
Abscess or phlegmon | N | 2 (10) | 3 (16) | 0.511 |
Erysipelas | N | N | 1 (5) | 0.484 |
Sepsis of unknown origin | N | 1 (5) | 2 (11) | 0.587 |
Clinical outcome survived/died, n (%) | 6 (86) / 1 (14) | 18 (90) / 2 (10) | 15 (79) / 4 (21) | 0.629 |